The Canadian Rheumatology Association (CRA) has issued an update to its position statement on biosimilars. In the document, the CRA says that evidence for the risk/benefit ratio for biosimilars is accruing rapidly, and physicians must demonstrate fiscal responsibility while providing the best care possible to individual patients.
The Canadian Rheumatology Association (CRA) has issued an update to its position statement on biosimilars. In the document, the CRA says that evidence for the risk/benefit ratio for biosimilars is accruing rapidly, and physicians must demonstrate fiscal responsibility while providing the best care possible to individual patients.
According to the position, for patients who are new to biologic therapy, cost-effectiveness must be considered whenever there is a choice between a reference and a biosimilar product. For patients who are already taking biologics, “a respectful and informed conversation between the rheumatologist and patient” must take place before transitioning to a biosimilar option.
Substitution by anyone other than the prescriber, says the CRA, should involve notification of both the prescriber and patient, and no substitution should occur without an informed consultation of the patient. Six months, says the CRA, would be an appropriate time frame in which to carry out these discussions. Patients who have clinically relevant disease flares in the first 6 months of treatment should be allowed to change back to the reference.
If nonmedical substitution is imposed by a third party, it is imperative that there not be an interruption in patient care; access to the reference product must remain stable until the biosimilar is made available.
CRA also emphasizes that no additional costs should be incurred by the patient as a result of a transition, and it encourages drug makers to provide adequate patient support programs.
The update to the group’s position comes as Canada makes major steps toward adopting biosimilars; earlier this week, British Columbia announced that it would switch patients taking reference biologics of infliximab, etanercept, and insulin glargine for rheumatological diseases and diabetes to biosimilars within 6 months.
Furthermore, officials noted, patients who receive biologics for inflammatory bowel disease will also be switched to biosimilars, and details concerning this patient population’s switching program will be made available shortly.
Additionally, the nation’s health technology assessment body, the Canadian Agency for Drugs and Technologies in Health (CADTH), announced recently that, as of June 1, it will no longer work on reviews of biosimilars, saying that there is no longer a need to continue offering these reviews.
The current process, which had already been streamlined from a previous and more labor-intensive process, involves gathering cost information and gathering stakeholder input from patients, clinicians, and jurisdictions. Even this faster approach, says CADTH, could have the unintended effect of delaying biosimilar access, and stopping reviews of biosimilars will allow CADTH to redeploy its resources to other drug review programs.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.